Lauren Leonard

Lauren is a corporate attorney who provides strategic counsel to public and private life sciences and technology companies throughout their life cycle. Lauren’s practice focuses on life sciences partnering transactions, including licensing arrangements, strategic collaborations and alliances, technology acquisitions and development, services, distribution, manufacturing, supply, clinical trial and other commercial agreements. Lauren regularly advises companies at all stages of growth regarding intellectual property-related issues and other general corporate matters, including formation and corporate governance, protection of intellectual property, financing and contract negotiations.

Lauren’s recent representative matters:

• A multinational pharmaceutical company in its $5.3 billion exclusive worldwide collaboration and license agreement with a biotechnology company to co-develop and co-commercialize a foundational therapy for overweight and obesity patients*
• An antibody services and technology provider in library development agreements with various partners and in its acquisition by a global provider of life sciences service solutions*
• A biotechnology company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring in its exclusive worldwide license and collaboration agreement with a multinational pharmaceutical company for the development of a radiotherapeutic candidate for cancer*
• A clinical-stage genetic medicine company in its global research collaboration focused on discovering and developing in vivo gene-editing therapy for liver disease*
• A clinical-stage revenue-generating global antibody engineering company in the sale of its radiopharmaceutical business to a global commercial-stage biopharmaceutical company*
• A public biopharmaceutical company in its $1 billion exclusive license agreement with a global pharmaceutical and healthcare company for an oral non-incretin development candidate in obesity and associated metabolic disorders*
• A biopharmaceutical company in the acquisition of its emerging gene therapies for inherited retinal diseases by a clinical-stage gene therapy company*

* Representation handled before joining Cooley